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Adult T-cell leukaemia (ATL) is a lethal neoplasia derived from HTLV-1-infected T lymphocytes frequently exhibiting nuclear factor-
kB (NF-kB) activation. Despite the use of various treatment regimens, the prognosis of ATL is poor, and new treatment strategies
are urgently needed. We therefore explored the effect and the molecular mechanism of a proteasome inhibitor, bortezomib, in ATL
cells. We found bortezomib-induced cell death, and bortezomib suppressed constitutive NF-kB activation via I-kB stabilisation in
three ATL cell lines (TaY, MT-2 and MT-4). An oligonucleotide DNA microarray analysis of TaY cells revealed upregulation of genes
encoding heat shock proteins (HSPA1A, STIP1, HSPA1B, and HSPCA), genes related to protein folding (CDC37 and ANAPC5), Fas-
associated factor 1(FAF1) and an oxidative stress-related gene, heme oxygenase-1(HMOX-1), known to be a target gene of hypoxia-
inducible gene-1 alpha (HIF-1 alpha). Cobalt protoporphyrin induced HMOX-1, instead of HIF-1 alpha expression and increased
bortezomib-induced apoptosis in the presence of pharmacologically effective doses of bortezomib. In contrast, zinc protoporphyrin
downregulated HMOX-1 expression, thereby partially inhibiting bortezomib-induced cell death. This indicates that HMOX-1 may
modulate anticancer effects of bortezomib in ATL cells, and could be a molecular target in treating ATL patients.
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Adult T-cell leukaemia/lymphoma (ATL), an aggressive malig-
nancy of CD4þ lymphocytes, is caused by the retrovirus HTLV-1
(Matsuoka and Jeang, 2005). Adult T-cell leukaemia/lymphoma is
resistant to chemotherapy and has a very poor prognosis, which
underlines the need for new therapeutic approaches. Leukaemia is
preceded by oligoclonal expansion of HTLV-1-infected activated T
cells, as a result of the viral transactivator protein Tax expression,
which activated various cellular genes including CREB/ATF, AP1,
and NF-kB (Sun and Yamaoka, 2005).
Activated nuclear factor-kappa B (NF-kB) was reported in
HTLV-1-associated cells, and has been implicated in resistance to
anticancer agents and apoptosis. In resting lymphocytes, NF-kBi s
sequestrated in cytoplasm, where it is inactivated by association
with inhibitory I-kB subunit (Pierce et al, 1997). Upon stimulation,
I-kBa protein is phosphorylated, and subsequently degraded by
the proteasome, resulting in the release of an active NF-kB that
translocates into the nucleus and subsequently activates the
transcription of the target genes (Karin and Ben-Neriah, 2000).
Tax can activate the NF-kB pathways through direct interaction
with the IKK complex, which causes I-kBa to be phosphorylated,
ubiquitylated, and subsequently degraded by proteasomes; how-
ever, de novo ATL cells frequently lose Tax expression, thereby
escaping from cytotoxic T lymphocytes (Furukawa et al, 2006).
The proteasome inhibitor, bortezomib (also known as VEL-
CADE or PS-341), represents a new class of anticancer drugs which
has been shown to inhibit the growth and/or progression of human
cancers, including multiple myeloma (Mitsiades et al, 2002;
Rajkumar et al, 2005; Cavo, 2006; Fisher et al, 2006). Although it
has been theoretically hypothesised that bortezomib abrogates the
degradation of I-kB, which blocks the transcriptional activity of
NF-kB, recent studies demonstrated that bortezomib elicits
activation of multiple pathways in cancer cells, such as endo-
plasmic reticulum (ER) stress and reactive oxygen species (ROS)
pathways (Fribley et al, 2004; Nawrocki et al, 2005; Obeng et al,
2006; Pe ´rez-Gala ´n et al, 2006; Yang et al, 2006). More recently,
HIF-1 alpha has been shown to determines the sensitivity of
endothelial cells to the proteosome inhibitor bortezomib (Veschini
et al, 2007).
Despite the fact that bortezomib affects several pathways critical
for the survival of HTLV-1-positive and -negative malignant T cells
(Satou et al, 2004; Nasr et al, 2005), the underlying mechanism by
which bortezomib inhibits ATL cell growth has not been fully
elucidated. We therefore attempted to clarify the molecular
pathway which might be involved in bortezomib-induced cell
death.
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sMATERIALS AND METHODS
Reagents and cell cultures
Bortezomib was kindly provided by Millennium Pharmaceuticals
Inc. (Cambridge, MA, USA). In all experiments, an IL-2-dependent
ATL cell line, TaY, which has been established and well
characterised in our laboratory (Zhou et al, 1998; Ojima et al,
2005; Takaku et al, 2005), was used in this study. Early passages of
TaY cells were retrieved and grown in RPMI 1640 with 10% FBS
and 20Uml
 1 of IL-2 (Roche Diagnostics, Mannheim, Germany).
Two IL-2-independent ATL cell lines (MT-2 and MT-4) (Miyoshi
et al, 1982), and an HTLV-1-negative T-cell line (Jurkat) (Gillis and
Watson, 1980) were also used in a part of our study. After obtaining
written informed consent, peripheral blood mononuclear cells
(PBMCs) were isolated from two patients with ATL by Ficoll-
Hypaque. Cobalt protoporphyrin (CoPP) was purchased from
Frontier Scientific (Logan, UT, USA). Zinc protoporphyrin (ZnPP)
was purchased from Alexis Biochemicals (San Diego, CA, USA).
Cell viability and apoptosis assay
The inhibitory effect of bortezomib on cell growth was assessed by
a cell counting kit (Wako Chemicals, Tokyo, Japan). Briefly, the
cells (5000well
 1) were incubated in triplicate in a 96-well plate in
the presence or absence of indicated test samples at a final volume
of 0.1ml for 24h at 371C. Thereafter, 0.01ml of tetrazolium salt,
WST-1 was added to each well. After 2-h incubation at 371C, the
optical density (OD) at 450nm was measured using a 96-well
multiscanner autoreader with the extraction buffer used as a blank.
Cell viability was expressed as a percentage (OD of the experiment
sample/OD of the control 100). For detection of apoptosis, the
Annexin V-binding capacities of the treated cells were examined
by the Annexin V-biotin apoptosis detection kit (Calbiochem, La
Jolla, CA, USA) using an Agilent 2100 Bioanalyzer (Agilent,
Wilmington, DE, USA), according to the supplier’s instructions.
Evaluation of NF-jB activity
The DNA-binding activity of NF-kB was quantified by enzyme-
linked immunosorbent assay (ELISA) using Trans-AM NF-kB p65
Transcription factor assay kit (Active Motif North America,
Carlsbad, CA, USA).
Western blotting
Cells were washed twice in phosphate-buffered saline (PBS) and
cell pellets were lysed in electrophoresis buffer and boiled for
10min. The equivalent of 30mg protein was loaded onto each lane
of a 10% tris-glycine gel. The separated protein was blotted onto a
filter. After blockage of nonspecific binding sites with BlockAce
(Dainippon-Sumitomo Pharma, Osaka, Japan), the filter was
incubated with antibodies for 60min at room temperature; anti-
IkB (Abcam Plc, Cambridge, UK), anti-HMOX-1 (Stressgen
Bioreagents, Ann Arbor, MI, USA), anti-HIF (Novus Biologicals,
Inc., Littleton, CO, USA) and anti-GAPDH (Abcam Plc). After
washing, the blots were incubated for 60min with horseradish
peroxidase (HRP)-linked anti-mouse IgG (Amersham Biosciences,
Buckinghamshire, UK). Signals were visualised using an ECL
western blotting detection reagents and analysis system (Amer-
sham Biosciences).
RNA isolation and labelling
TaY cells were treated with 0.5–100nM of bortezomib for 24h.
After treatment, cells were harvested, and total RNA was extracted
using an RNeasy Mini Kit (Qiagen, Germantown, MD, USA). The
amount of RNA was measured by NanoDrop (NanoDrop
Technologies, Wilmington, DE, USA), then the quality of extracted
RNA was checked using a 2100 Bioanalyzer (Agilent Technologies,
Wilmington, DE, USA). A Label Star array kit (Qiagen) was used
for cDNA labelling according to the supplier’s instructions as
reported previously (Zhang et al, 2006).
Oliginucleotide DNA microarray
We designed a pathway-focused low-density oligonucleotide
microarray (Novusgene Inc., Tokyo, Japan) which contains 667
selected genes related to cell growth, cell cycle, apoptosis,
transcription, DNA repair and cell stress responses (GPL 3837).
For dual-colour analysis, cDNA obtained from untreated TaY cells
was labelled with Cy3 as a reference, and cDNA obtained from the
bortezomib-treated cells was labelled with Cy5. Hybridisation was
carried out automatically using GeneTAC Hybstation (Genomic
Solutions, Ann Arbor, MI, USA), as reported previously (Takaku
et al, 2005).
Data analysis and statistic validation
The hybridisation signals were scanned by GenePix 4000B (Axon
Instruments, Union City, CA, USA). For statistical analysis of gene
expression, we utilised a GeneSifter
s (VizXLabs, Seattle, WA,
USA). Analysis of variance (ANOVA) and Student’s t-test were
done using GeneSifter
s. P-values of less than 0.05 were considered
to indicate a statistically significant difference and the Benjamini–
Hochberg algorithm was used for estimation of false discovery
rates (Zhang et al, 2006).
Real-time reverse transcriptase–PCR (RT–PCR)
To confirm the microarray results, we performed RT–PCR by ABI
Prism 7700 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) as reported elsewhere (Ohyashiki et al,
2005). We utilised Taqman gene expression assays (Applied
Biosystems), and the amount of gene expression in each sample
was evaluated as a percent with respect to the standard curve
generated from a serial dilution of quantitative PCR human
reference total RNA (Stratagene, La Jolla, CA, USA). The obtained
data from GAPDH were used to standardise the sample variation
in the amount of input cDNA.
RESULTS
Bortezomib-induced cell death in ATL cell lines
We first examined the effect of bortezomib on ATL cell lines, TaY,
MT-2, MT-4 and a HTLV-1-negative T-cell line, Jurkat, in vitro by
a cell-counting assay. The median inhibitory concentration (IC50)
of bortezomib for TaY was 5nM, that for MT-2 was 4.5nM, that for
MT-4 was 10nM and that for Jurkat was 30nM, respectively
(Figure 1A). The expression level of Tax was not affected by
bortezomib-treated ATL cells (data not shown). To study whether
or not the cell death induced by bortezomib was apoptosis, we
analysed the bortezomib-induced cell death by annexin V staining.
Cells were treated for 24h with different concentrations of
bortezomib, then stained with annexin V-Cy5. The results showed
apoptosis in a dose-dependent manner, indicating that bortezomib
induced apoptosis of ATL cell lines (Figure 1B); cell death was also
confirmed by morphology (Supplementary file).
Bortezomib suppresses constitutive NF-jB activation via
I-jB stabilisation in ATL cell lines
We then investigated the DNA binding of NF-kB by an ELISA
assay. Cells were treated with bortezomib for different periods of
time. We found the DNA-binding capacity of NF-kB decreased in a
time-dependent manner, indicating an inhibitory effect of 5nM of
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sbortezomib on NF-kB activation in TaY cells (Figure 2A). The
decreased activity of NF-kB was also evident in MT-2 and MT-4
after 3h exposure to bortezomib; DNA-binding activity of NF-kB
after bortezomib treatment was 26.8% in MT-2 and 17.0% in MT-4
cells, respectively, compared to those in untreated cells. In order to
clarify the inhibitory effect of bortezomib on the NF-kB/I-kB
cascade, we analysed the protein level of I-kBa in TaY cells after
24h treatment with bortezomib. Consistent with the decreased
DNA-binding activity of NF-kB, bortezomib induced the accumu-
lation of I-kBa in TaY cells (Figure 2B). Accumulation of I-kBa was
also confirmed in MT-2 and MT-4.
Gene expression profile of bortezomib-treated TaY cells
To further understand how bortezomib induced apoptosis in ATL
cells, we used TaY cells treated with bortezomib or vehicle control
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Figure 1 (A) Cytotoxity of bortezomib on TaY, MT-2, MT-4 and Jurkat.
Cells were cultured in the presence or absence of increasing doses of
bortezomib (1–500nM). The percentage of viability is plotted with respect
to untreated cells. The results are shown as means (±s.d.) percentage of
viability from triplicate cultures with repeated experiments. (B) Bortezomib
induced apoptosis in ATL cell lines (TaY, MT-2 and MT-4). Cells were
cultured in the presence of bortezomib for 24h. Cell death was analysed by
an annexin V-biotin apoptosis detection kit. Apoptosis is expressed as a
percent of Annexin V-positive cells in bortezomib-treated cells.
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Figure 2 (A) DNA-binding capacity of NF-kB in TaY cells. TaY cells
were cultured in the presence of bortezomib for the indicated periods
(0–180min), harvested and subjected to EMSA. (B) Expression of I-kBa in
TaY cells. Whole cell extracts (30mg/lane) of TaY cells are immunoblotted
with specific antibodies against I-kBa and GAPDH. Accumulation of I-kBa
and phosphorylated I-kBa were observed in a dose-dependent manner.
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Figure 3 The molecular signature of bortezomib-treated TaY cells.
ANOVA analysis was performed by GeneSifter
s using microarray analysis
data deposited in GEO (GSE5794). Genes whose expression levels are
greater (red) or lower (green) in bortezomib-treated TaY cells compared
to those in untreated cells were navigated by GeneSifter
s. They are also
listed in Table 1.
Molecular targets of bortezomib in ATL cells
RS Hamamura et al
1101
British Journal of Cancer (2007) 97(8), 1099–1105 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sfor short time periods, and microarray analysis was performed
using in-house prepared oligonucleotide DNA microarrays (NCBI
Gene expression omnibus, GSE5794, unreleased). Differential
expression was analysed using a GeneSifter
s (Figure 3). Upregu-
lated or downregulated genes in bortezomib-treated TaY cells
(expression level in the sample was four-fold greater or lower than
in untreated TaY cells) are summarised in Table 1. In TaY cells,
bortezomib induced upregulation of genes encoding heat shock
proteins (HSPA1A, STIP1, HSPA1B and HSPCA), genes related to
protein folding (CDC37 and ANAPC5) and Fas-associated factor
1(FAF1) known as an apoptosis facilitator. Upregulation of
HMOX-1, which is known to be a target gene of hypoxia-inducible
gene-1 alpha (HIF-1 alpha), was notable in bortezomib-treated
TaY cells. The results obtained from microarray data were
consistent with those analysed by real-time RT–PCR and the
induction of HMOX-1 after treatment with pharmacological
concentrations of bortezomib was more than 100-fold compared
to untreated cells (Figure 4C). Downregulation of vascular
endothelial growth factor (VEGF) beta, IL6 and BCL2 were also
evident, as previously identified in human multiple myeloma cells
following bortezomib-induced apoptosis. Downregulation of a
subset of cytokines and cytokine receptors (i.e. IL1R1, IL18R1,
IL23A) was also noted.
Induction of HMOX-1 by CoPP enhances the antitumour
effect of bortezomib in ATL cells
Based on the results obtained from the differential expression
pattern, we in particular focused our study on a gene closely
related to oxygen stress, i.e., HMOX-1. To determine the possible
role of HMOX-1 in bortezomib-induced apoptosis in TaY cells, we
examined the change of apoptotic effect by adding the HMOX-1
inducer, CoPP, or the HMOX-1 inhibitor, ZnPP. Although CoPP
and ZnPP did not affect the cell growth of TaY cells in the absence
of bortezomib (data not shown), we found that CoPP significantly
enhanced the cytotoxity and bortezomib-induced apoptosis in TaY
cells (Figure 4A and B). In contrast, ZnPP partially inhibited
bortezomib-induced cell death in TaY cells with pharmacologically
effective dose of bortezomib (Figure 4A and B). Real-time RT–
PCR and western blot analysis revealed that CoPP significantly
enhanced HMOX-1 in TaY cells (Figure 4C and D). To determine
whether HMOX-1 induced the antiproliferative activity of borte-
zomib via HIF-1 alpha or not, we performed real-time RT–PCR;
however, upregulation of HIF-1 alpha was not evident (Figure 4E
left). Western blot analysis also revealed that HIF-1 alpha was not
significantly elevated after treatment of bortezomib in TaY cells
(Figure 4E right). This indicates that upregulation of HMOX-1
rather than HIF-1 alpha affects the antitumour effect of
bortezomib.
To ascertain whether involvement of HMOX-1 in bortezomib-
induced cell death is not restricted in TaY cells, we analysed the
effect of CoPP in MT-2 and MT-4. Upregulation of HMOX-1 by
CoPP enhanced sensitivity to bortezomib in MT-2 and MT-4,
indicating that this phenomenon is consistent with the results
obtained from TaY cells (Figure 5A).
Gene expression levels of HMOX-1 in bortezomib-treated
ATL patient’ sample
To validate whether genes extracted in the current study indeed
reflect molecular pathways in bortezomib-treated ATL cells, we
analysed the gene expression levels of HMOX-1 in bortezomib-
Table 1 Identification of genes affected by bortezomib treatment
Gene accession # Gene name P-value (ANOVA)
(a) Upregulated genes whose expression level was greater than four-fold compared to those in untreated cells
NM_005345 HSPA1A Heat shock 70kDa protein 1A 0.000012
NM_006819 STIP1 Stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein) 0.000037
NM_007065 CDC37 CDC37 cell division cycle 37 homologue 0.000036
NM_005346 HSPA1B Heat shock 70kDa protein 1B 0.000001
NM_002133 HMOX1 Heme oxygenase (decycling) 1 0.015313
NM_007355 HSPCB Heat shock protein 90kDa alpha (cytosolic), class B member 1 (HSP90AB1) 0.000033
NM_000163 GHR Growth hormone receptor 0.001547
NM_080738 EDARADD EDAR-associated death domain 0.000078
NM_005348 HSPCA Heat shock protein 90kDa alpha (cytosolic), class A member 1 (HSP90AA1), transcript variant 2 0.00178
NM_005526 HSF1 Heat shock transcription factor 1 0.006578
NM_007051 FAF1 Fas (TNFRSF6)-associated factor 1 0.006247
NM_016237 ANAPC5 Anaphase-promoting complex subunit 5 0.011988
(b) Downregulated genes whose expression level was lower than four-fold compared to those in untreated cells
NM_000877 IL1R1 Interleukin 1 receptor, type I 0.012833
NM_000345 SNCA Synuclein, alpha 0.000001
NM_006569 CGREF1 Cell growth regulator with EF-hand domain 1 0.004154
NM_138556 TLR4 Toll-like receptor 4 0.000122
NM_001242 TNFRSF7 Tumour necrosis factor receptor superfamily, member 7 0.000002
NM_003855 IL18R1 Interleukin 18 receptor 1 0.007924
NM_020529 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 0.000013
NM_015675 GADD45B Growth arrest and DNA-damage-inducible, beta 0.000001
NM_003592 CUL1 Cullin 1 0.008025
NM_004780 TCEAL1 Transcription elongation factor A (SII)-like 1 0.000001
NM_003377 VEGFB Vascular endothelial growth factor B 0.000002
NM_003212 TDGF1 Teratocarcinoma-derived growth factor 1 0.000759
NM_000600 IL6 Interleukin 6 0.01754
NM_000633 BCL2 B-cell CLL/lymphoma 2 (BCL2) 0.000054
NM_003199 TCF4 Transcription factor 4 0.000052
NM_016584 IL23A Interleukin 23, alpha subunit p19 0.000001
NM_030756 TCF7L2 Transcription factor 7-like 2 0.000006
List of genes in Table 1 correspond to the heat map shown in Figure 3. Gene accession number, full name of each gene and statistical significance are shown above.
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streated TaY cells and ATL cells obtained from two patients. The
HMOX-1 expression level was remarkably elevated in bortezomib-
treated fresh ATL cells as well as an ATL cell line (TaY). This
indicates that the molecular pathway involving HMOX-1 may play
an important role in de novo ATL cells treated with bortezomib
(Figure 5B).
DISCUSSION
In this study, we demonstrated that the mechanism of the
antitumour effect of bortezomib on ATL cells involves oxygen-
dependent gene regulation in addition to the I-kBa /NF-kB
pathway. Based on the results obtained from gene expression
profiling, we in particular focused on HMOX-1, as representative
of oxygen-dependent gene regulation in bortezomib-induced
apoptosis. We found that bortezomib induced HMOX-1 expression
at the transcriptional level as well as at the protein level. HMOX-1,
an inducible enzyme that catalyses oxidative degradation of heme
to form biliverdin, carbon monoxide and free iron has recently
been implicated in the regulation of angiogenesis via VEGF activity
(Morse and Choi, 2005). Evidence suggests that expression of
HMOX-1 is induced in response to ROS (Morse and Choi, 2005).
Bortezomib was reported to induce ROS generation in various
cancer cells such as non-small-cell lung cancer, leukaemia cells,
and head and neck squamous cell carcinoma. ROS was therefore
implicated as the primary cause for bortezomib-induced apoptosis
of those cells (Ling et al, 2003; Fribley et al, 2004; Yu et al, 2004;
Landowski et al, 2005). Recent reports have demonstrated that
NF-kB indirectly inhibits ROS generation (Sakon et al, 2003;
Kamata et al, 2005); however, the intracellular ROS balance may be
regulated by multiple pathways, therefore, it is still uncertain
whether ROS generation is due to NF-kB/I-kB inhibition cascade
in bortezomib-treated cancer cells.
Oxygen regulation is a complex process that has special
relevance in the progression of cancer. Cells subjected to hypoxia
(reduced ability of oxygen) undergo transcriptional changes that
promote increased anaerobic metabolism, angiogenesis and other
adaptive responses (Semenza, 2003). The key mediator of these
changes is the transcription factor HIF-1, a heterodimer of the
protein subunits HIF-1 alpha, which is induced by hypoxia and
HIF-1 beta, which is constitutively expressed (Wang et al, 1995).
HIF-1 alpha protein is mainly regulated post-transcriptionally by
inhibiting its ubiquitination and proteolysis (Huang et al, 1998). It
is known that HIF-1 alpha ultimately leads to HIF-1-regulated gene
expression, such as HMOX-1 and VEGF (Bussolati and Mason
(2006)). We therefore assumed that bortezomib induced upregula-
tion of HIF-1 alpha by inhibiting proteolysis, thereby, upregulation
of HMOX-1 via HIF-1 alpha leads to bortezomib-induced cell
death. In the current study, however, upregulation of HIF-1 alpha
was not evident at either the transcriptional level or the protein
level in TaY cells.
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Figure 4 Effect of CoPP and ZnPP in bortezomib-induced cell death. TaY cells were cultured with CoPP or ZnPP in the presence of bortezomib. (A) The
percentage of cell viability was plotted with respect to untreated cells. (B) Apoptosis was expressed as fold increases of annexin V-positive cells
in bortezomib-treated cells compared to those in untreated cells. (C) Fold induction (or reduction) of HMOX gene expression measured by real-time
RT–PCR. (D) Western blotting of HMOX-1 and GAPDH. Fold increases were expressed as a signal of HMOX-1/GAPDH in the specimen with respect to
those in untreated cells. (E) HIF-1 alpha expression in bortezomib-treated TaY cells (real-time RT–PCR, left; western blotting, right).
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inducer of HMOX-1 in many tissues. Unlike haem, CoPP is neither
a pro-oxidant nor a substrate for HMOX-1, therefore, it might be
considered as a potential therapeutic agent in situations where
upregulation of HMOX-1 is desired. In the current study, CoPP
induced HMOX-1 expression. Instead, HIF-1 alpha expression was
downregulated by CoPP, possibly due to a feedback mechanism for
upregulation of HMOX-1. This further suggests that bortezomib
modulates the oxygen-dependent gene regulation, and induction of
oxygen-dependent genes may serve as a feedback mechanism to
balance the intracellular level of ROS. Since HIF-1 alpha activates
the transcription of genes that are involved in cell survival as well
as apoptosis, we could not completely rule out the possibility that
subtle change of HIF-1 alpha modulates bortezomib-induced cell
death via pathways other than those involving HMOX-1. To the
best of our knowledge, this is the first report that induction of
HMOX-1 by CoPP enhances bortezomib-induced apoptosis.
Although we were able to identify only a limited number of
genes related to bortezomib-induced cell death in ATL cells, we
demonstrated that HMOX-1 regulation plays an important role in
the antitumour activity of bortezomib. Since the number of
patients studied was too small to draw a definite conclusion, it
should obviously be clarified in large numbers of patient specimen;
however, the enhanced sensitivity of ATL cells to bortezomib by
CoPP is intriguing and suggests that HMOX-1 may be an attractive
target for treating ATL patients.
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Figure 5 (A) Induction of HMOX-1 by CoPP enhances apoptotic
effects of bortezomib in MT-2 and MT-4 cells. Fold increase of HMOX-1
mRNA is shown at the bottom of the graph. (B) Comparison of gene
expression levels between cell line (TaY) and patient sample. Percent of
ATL cells in the blood specimens is 46% in patient no.1 and 82% in patient
no. 2, respectively. Relative gene expression levels are expressed as ratios
(copy numbers of target gene/copy numbers of GAPDH). In the presence
of bortezomib, upregulation of HMOX-1 is evident in both TaY cells and
patient samples.
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